Intrahepatic Cholangiocarcinoma
📧 Sign up to get email alerts when something new happens for Intrahepatic Cholangiocarcinoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2024-07-11Clinical Trial Update: Study of Irinotecan Liposome Injection in Patients With Advanced Biliary Tract Cancer [Phase 2]
A Phase 2 study of irinotecan liposome injection in patients with advanced biliary tract cancer has been terminated.
-
CLINICAL_TRIALS trial_result · 2024-05-22Clinical Trial Update: Lenvatinib and Adebrelimab Combined With GEMOX in the Perioperative Treatment of Potentially Resectable Intrahepatic Cholangiocarcinoma [Phase 4]
Phase 4 trial evaluating a combination of lenvatinib, adebrelimab, and GEMOX as perioperative treatment for potentially resectable intrahepa…
-
CLINICAL_TRIALS trial_result · 2024-03-04Clinical Trial Update: Recombinant Human Adenovirus Type 5 Plus HAIC of FOLFOX for Intrahepatic Cholangiocarcinoma [Phase 4]
Phase 4 clinical trial update evaluating recombinant human adenovirus type 5 combined with HAIC of FOLFOX for intrahepatic cholangiocarcinom…
-
CLINICAL_TRIALS trial_result · 2024-01-09Clinical Trial Update: Combined DEB-TACE, Lenvatinib and Pucotenlimab as Conversion Therapy for Unresectable Intrahepatic Cholangiocarcinoma [Phase 2]
Phase 2 trial evaluating a combo of DEB-TACE, lenvatinib, and pucotenlimab as conversion therapy for unresectable intrahepatic cholangiocarc…
-
CLINICAL_TRIALS trial_result · 2023-12-19Clinical Trial Update: Derazantinib in Subjects With FGFR2 Gene Fusion-, Mutation- or Amplification- Positive Inoperable or Advanced Intrahepatic Cholangiocarcinoma [Phase 2]
Phase 2 trial of derazantinib in FGFR2-altered intrahepatic cholangiocarcinoma and related conditions completed; results posted in 2023.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2023-11-29Clinical Trial Update: Combined Therapy Using D-TACE, Gemcitabine and Cisplatin, and PD1 Antibody in Advanced and Unresectable Intrahepatic Cholangiocarcinoma [Phase 2]
Phase 2 clinical trial investigating combined therapy with D-TACE, gemcitabine, cisplatin, and a PD-1 antibody for unresectable intrahepatic…
-
CLINICAL_TRIALS trial_result · 2023-11-18Clinical Trial Update: Combination Therapy of HAIC, Surufatinib and Tislelizumab for Unresectable or Metastatic Biliary Tract Cancer [Phase 2]
Phase 2 clinical trial investigating a combination of hepatic artery infusion chemotherapy (HAIC), surufatinib, and tislelizumab for unresec…
-
CLINICAL_TRIALS trial_result · 2023-11-02Clinical Trial Update: Cadonilimab Combined With Gem/Cis as First Line Therapy in Patients With Advanced ICC [Phase 2]
Phase 2 trial update evaluating cadonilimab with gemcitabine/cisplatin as first-line therapy for advanced intrahepatic cholangiocarcinoma.
-
CLINICAL_TRIALS trial_result · 2023-06-22Clinical Trial Update: Pemigatinib Combined With PD-1 Inhibitor in Unresectable or Metastatic Intrahepatic Cholangiocarcinoma [Phase 2]
Phase 2 trial evaluating pemigatinib in combination with a PD-1 inhibitor for unresectable or metastatic intrahepatic cholangiocarcinoma is …
-
CLINICAL_TRIALS trial_result · 2023-05-31Clinical Trial Update: Cryoablation Combined With Sintilimab Plus Lenvatinib in 1L Treatment of Advanced ICC (CASTLE-ICC-Chemo-free) [Phase 2]
Phase 2 trial evaluating cryoablation with sintilimab and lenvatinib as first-line therapy for advanced intrahepatic cholangiocarcinoma; sta…
-
CLINICAL_TRIALS trial_result · 2023-04-21Clinical Trial Update: Copper Cu 64 Anti-CEA Monoclonal Antibody M5A PET in Diagnosing Patients With CEA Positive Cancer [NA]
Clinical trial update for M5A, a Copper-64 labeled anti-CEA monoclonal antibody used in PET imaging to diagnose CEA-positive cancers; the st…
-
CLINICAL_TRIALS trial_result · 2023-04-19Clinical Trial Update: Camrelizumab in Combination With Apatinib in Advanced ICC: A Single-arm Phase II Study [Phase 2]
Phase II single-arm trial evaluating camrelizumab with apatinib for advanced intrahepatic cholangiocarcinoma.
-
CLINICAL_TRIALS trial_result · 2023-04-13Clinical Trial Update: HAIC Combined With Sintilimab and Bevacizumab for Unresectable Intrahepatic Cholangiocarcinoma [Phase 2]
Phase 2 trial update exploring HAIC with sintilimab and bevacizumab for unresectable intrahepatic cholangiocarcinoma.
-
CLINICAL_TRIALS trial_result · 2023-03-31Clinical Trial Update: Durvalumab and SNDX-6532 Following Chemo or Radio-Embolization for Patients With Intrahepatic Cholangiocarcinoma [Phase 2]
Phase 2 trial evaluating the combination of durvalumab and SNDX-6532 after chemotherapy or radioembolization in patients with unresectable i…
-
CLINICAL_TRIALS trial_result · 2023-01-25Clinical Trial Update: A Study of FT-2102 in Patients With Advanced Solid Tumors and Gliomas With an IDH1 Mutation [Phase 1, Phase 2]
Phase 1/2 trial evaluating FT-2102 in IDH1-mutant advanced solid tumors and gliomas; study completed with posted results.
-
CLINICAL_TRIALS trial_result · 2023-01-05Clinical Trial Update: Durvalumab Combined With GemCis Neoadjuvant Therapy of Resectable Intrahepatic Cholangiocarcinoma With High Recurrence Risk [Phase 2]
Phase 2 trial evaluating durvalumab in combination with gemcitabine/cisplatin neoadjuvant therapy for resectable intrahepatic cholangiocarci…
-
CLINICAL_TRIALS trial_result · 2022-11-17Clinical Trial Update: Tislelizumab Combined With Lenvatinib and GEMOX Versus Tislelizumab Combined With GEMOX in Conversion Therapy of ICC and GBC. [Phase 2]
Phase 2 trial comparing tislelizumab plus lenvatinib and GEMOX versus tislelizumab plus GEMOX for conversion therapy in potentially resectab…
-
CLINICAL_TRIALS trial_result · 2022-09-10Clinical Trial Update: Second Line Therapy for Advanced Intrahepatic Cholangiocarcinoma [Phase 2]
Phase 2 clinical trial update on second-line therapy for advanced intrahepatic cholangiocarcinoma.
-
CLINICAL_TRIALS trial_result · 2022-08-18Clinical Trial Update: Adjuvant PD-1 Antibody in Combination With Capecitabine for Patients With ICC at High-Risk of Postoperative Recurrence [Phase 1, Phase 2]
A clinical trial exploring adjuvant PD-1 antibody in combination with capecitabine for intrahepatic cholangiocarcinoma at high risk of recur…
-
CLINICAL_TRIALS trial_result · 2022-08-05Clinical Trial Update: HAIC Combined With Tislelizumab and Apatinib for Unresectable Intrahepatic Cholangiocarcinoma [Phase 2]
Phase 2 trial investigating HAIC with tislelizumab and apatinib for unresectable intrahepatic cholangiocarcinoma is ongoing; current status …
-
CLINICAL_TRIALS trial_result · 2022-03-24Clinical Trial Update: Percutaneous Hepatic Perfusion vs. Cisplatin/Gemcitabine in Patients With Intrahepatic Cholangiocarcinoma [Phase 2, Phase 3]
Clinical trial update comparing Percutaneous Hepatic Perfusion to Cisplatin/Gemcitabine in intrahepatic cholangiocarcinoma (bile duct cancer…
-
CLINICAL_TRIALS trial_result · 2022-02-23Clinical Trial Update: Sintilimab Combined With GEMOX ± IBI305 (Bevacizumab Biosimilar) Versus GEMOX in Advanced Intrahepatic Cholangiocarcinoma [Phase 2]
Phase 2 trial update evaluating sintilimab with GEMOX ± IBI305 (bevacizumab biosimilar) versus GEMOX in advanced intrahepatic cholangiocarci…
-
CLINICAL_TRIALS trial_result · 2022-02-02Clinical Trial Update: Gemcitabine Hydrochloride, Cisplatin, and Nab-Paclitaxel in Treating Patients With Advanced or Metastatic Biliary Cancers [Phase 2]
Phase 2 trial evaluating gemcitabine hydrochloride, cisplatin, and nab-paclitaxel for advanced or metastatic biliary cancers has completed w…
-
CLINICAL_TRIALS trial_result · 2022-01-13Clinical Trial Update: Drug-Eluting Bead, Irinotecan Therapy for Unresectable Intrahepatic Cholangiocarcinoma w/Concomitant Gemcitabine and Cisplatin or Carboplatin [Phase 2]
A Phase 2 clinical trial evaluating irinotecan-eluting beads with gemcitabine and cisplatin or carboplatin for unresectable intrahepatic cho…
-
CLINICAL_TRIALS trial_result · 2021-07-14Clinical Trial Update: HAIC With FOLFOX Versus Systemic Chemotherapy With GP for Unresectable ICC [Phase 3]
Phase 3 trial comparing hepatic arterial infusion chemotherapy with FOLFOX to systemic GP chemotherapy for unresectable intrahepatic cholang…